Fulcrum Therapeutics, Inc

Track all markets on TradingView Fulcrum Therapeutics, Inc. (NASDAQ: FULC) recently released its SEC report for the year 2022. Notably, the lease expenses reported by the company for its property at 26 Landsdowne Street amounted to approximately $1.9 million for the year. The lease for the space, which covers 5.5 years starting from December 2021, […]

Track all markets on TradingView Fulcrum Therapeutics, Inc. (ticker: FULC), a biotechnology company focused on developing treatments for genetically defined diseases, has recently released its annual financial report for the year ended December 31, 2022. The company’s collaboration revenue from various agreements has grown significantly over the past year, particularly due to the MyoKardia Collaboration

Track all markets on TradingView Fulcrum Therapeutics, Inc. (ticker: FULC) has an impressive amount of cash equivalents and marketable securities in its financial portfolio. As of December 31, 2022, their total cash equivalents and marketable securities stood at $218.2 million. This figure represents the financial stability and growth potential of the company. In 2022, Fulcrum

Track all markets on TradingView Article: Biopharmaceutical company Fulcrum Therapeutics, Inc. (Ticker: FULC) has reported an operating lease right-of-use asset of $10.8 million as it adopted the Financial Accounting Standards Board’s (FASB) Accounting Standards Update (ASU) No. 2016-02, which is set to be effective from January 1, 2022. This comes as the company transitions its

Track all markets on TradingView Fulcrum Therapeutics, Inc. (ticker: FULC) is a clinical-stage biotechnology company focused on the development of therapies for severe diseases. The company’s latest SEC report provides insights into their research and development progress and their strategy to finance it. Fulcrum has been able to raise more than $380 million through multiple

Track all markets on TradingView Article: Fulcrum Therapeutics, Inc. (FULC), a biotechnology company focusing on genetically-defined rare diseases, has disclosed in its Form 10-K/A report filed with the Securities and Exchange Commission (SEC) that its disclosure controls and procedures were evaluated to be effective as of December 31, 2022. This evaluation was conducted by the

Track all markets on TradingView Fulcrum Therapeutics, Inc. (ticker: FULC), a biopharmaceutical company focusing on unlocking gene control to develop treatments for genetic diseases, has reported continued progress in its research and development activities for the fiscal year 2021, as per its recent SEC report on Form 10-K. Established in 2015 in Massachusetts, Fulcrum Therapeutics